Özet:

OBJECTIVE: In this study, the effect of pre-treatment neutrophil-to lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) on gynecological malignancies that applied radiotherapy and /or radiochemotherapy was investigated. MATERIAL AND METHODS: The data obtained from 82 patients who applied to our clinic between 2009- 2014 and developed recurrence and/or metastasis during their routine follow-up were retrospectively evaluated. Pre-treatment whole blood parameters of all patients were examined, and their effects on survival were analyzed by Kaplan Meier and the ROC curve. RESULTS: The median age was 57.5 (30-82), follow-up was 26 months. According to the blood values median WBC: 7.34, RBC: 4.33, hb: 11.7, hct: 36.4, MCV: 85.8, MCH: 27.6, MCHC: 32.1, plt: 270050, lymphocyte: 1,66, neutrophils: 4.79, monocytes: 0.56, eosinophils: 0.11, basophils: 0.1.Statistically; according to the ROC analysis, the boundary PLR value was 174 and the NLR value was 2.06. Overall survival rates were 2 and 3 years 78% , 57% . In univariate analysis the pre-treatment blood values; WBC > 7.34 (p = 0.01), the platelet value > 270050 (p = 0.021) and the absolute neutrophil value > 4.79 (p = 0.04) found to have a negative effect on survival. At the end of the ROC analysis, the NLR ratio was found to be above 2.06, adversely affecting survival (p = 0.005), but the PLR rate did not affect survival. CONCLUSIONS: In the future, the treatment method of patients diagnosed with gynecological cancer can be determined with a very simple and inexpensive blood test. High NLR before treatment can be used as a parameter indicating a more aggressive treatment approach may be required in patients.

Anahtar Kelimeler: